AZD-9793

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameAZD-9793
Drug Alias NameAZD-9793AZD9793
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionGlypican-3 modulatorsCluster of differentiation 8 modulatorsT-cell receptor modulators
TargetsGlypican-3Cluster of differentiation 8T-cell receptor
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanSpain +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstraZeneca global R & D (China) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A